revenue_growth

Toronto – October 12, 2026 -- Profound Medical Corp. expects third-quarter 2026 revenue of $9.8 million to $10.0 million, roughly 45% to 47% above the Bloomberg mean analyst consensus of $6.78 million.

Revenue nearly doubles year over year and almost quadruples sequentially

The preliminary, unaudited range implies growth of approximately 85% to 89% from $5.3 million in the third quarter of 2025. Compared with $2.5 million in the second quarter of 2026, revenue is expected to rise approximately 292% to 300%.

The Nasdaq- and TSX-listed company expects gross margin to exceed 70% for the quarter, again above that threshold. Profound attributes the margin to progress in its commercial operations and scale.

Aspen, Colo. – – October 08, 2026 -- 21X has appointed Adam Squire as president of 21X SPORTS, a new revenue platform targeting leagues, professional and minor league teams, collegiate athletic departments, and sports apparel companies seeking incremental revenue from existing fan relationships.

Squire brings a decade of sports industry operating experience to the new role

Squire joined CapStone Holdings in 2022 and currently leads sports operations for GameAbove Sports, managing professional athlete relationships and sports partnerships. His background spans collegiate athletics, golf technology and equipment investments, youth development initiatives, and signature events.

Nashville, Tenn. – September 12, 2026 -- EvidenceCare has named John Voigt Jr. as its first unified Chief Revenue Officer, consolidating sales and marketing under one executive as the clinical performance improvement platform enters its next growth phase.

Voigt brings a track record of scaling healthcare technology revenue functions

Voigt previously served as executive vice president of growth and strategy at ActiumHealth (Syllable AI), where he led commercial strategy for the company's AI-driven patient access platform. Before that, he directed health system growth strategy at Wellvana Health, building partnerships that generated more than $200 million in annual risk revenue. Earlier in his career, he helped grow Cedar's annual recurring revenue from $2 million to over $85 million.

Gothenburg – – September 08, 2026 -- Zinzino AB reported group revenue of SEK 282.2 million for August 2026, up 15% from SEK 245.9 million a year earlier, as growth in its direct-sales markets offset a sharp decline at subsidiary Faun Pharma.

Sales markets revenue climbs 16% to SEK 280.9 million in August

Zinzino's core direct-sales business generated SEK 280.9 million in August 2026, up from SEK 242.5 million in the same month last year, a 16% increase that drove the bulk of the group's top-line expansion.

Faun Pharma external sales drop to SEK 1.3 million from SEK 3.4 million

Faun Pharma's external sales fell to SEK 1.3 million in August 2026, down from SEK 3.4 million a year earlier, a decline that partially offset the stronger performance of Zinzino's sales markets and reduced the group's overall growth rate to 15% from the 16% posted by the sales markets alone.